A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants.
about
Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia.Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing RisksValidation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation.Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2.Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome.Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.Description of CD8 Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer
P2860
Q33611146-B6109E4D-7BDB-4068-9400-29B4E2748FFDQ34380060-9945B46E-0CDF-4B14-A264-61AA0CD12245Q35009266-40D6752F-66CD-4E14-A5ED-2D4E0EEDB702Q37422385-BAF20FC1-C799-4F06-8CB8-BAB9F2AD4453Q40525341-7794400A-EA63-4FA2-96ED-A60D9F9FB8C5Q41592261-337AECFC-437C-4CE9-B997-A165A6D86FFAQ41873361-F6F76DC8-9A77-46C2-B75C-941A113F40ECQ45233774-C7A4910D-D843-47BC-8814-228CE387217FQ45774394-7FBC1449-2BCC-478A-836C-66FFD75564BFQ48236706-FBE5A20D-9789-418D-B3AB-680DB112883FQ52870483-A10EEBC5-6B0B-4A7A-8252-336F9233AFD1Q52873870-4A7CC658-123E-4721-B4F5-76AF3B718309Q56890349-9B34B29E-A544-4A0A-B9DB-50FE7080E3AC
P2860
A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A modified EBMT risk score pre ...... ogeneic stem cell transplants.
@en
A modified EBMT risk score pre ...... ogeneic stem cell transplants.
@nl
type
label
A modified EBMT risk score pre ...... ogeneic stem cell transplants.
@en
A modified EBMT risk score pre ...... ogeneic stem cell transplants.
@nl
prefLabel
A modified EBMT risk score pre ...... ogeneic stem cell transplants.
@en
A modified EBMT risk score pre ...... ogeneic stem cell transplants.
@nl
P2093
P2860
P1476
A modified EBMT risk score pre ...... ogeneic stem cell transplants.
@en
P2093
Bernd Dörken
Gero Massenkeil
Lam G Vuong
Philipp G Hemmati
Philipp le Coutre
Renate Arnold
Theis H Terwey
P2860
P304
P356
10.1111/J.1600-0609.2011.01580.X
P577
2011-04-01T00:00:00Z